AR059809A1 - Anticuerpos anti-5t4 y sus usos - Google Patents

Anticuerpos anti-5t4 y sus usos

Info

Publication number
AR059809A1
AR059809A1 ARP070100988A ARP070100988A AR059809A1 AR 059809 A1 AR059809 A1 AR 059809A1 AR P070100988 A ARP070100988 A AR P070100988A AR P070100988 A ARP070100988 A AR P070100988A AR 059809 A1 AR059809 A1 AR 059809A1
Authority
AR
Argentina
Prior art keywords
antibodies
antibody
murine
antigen
binds
Prior art date
Application number
ARP070100988A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38445207&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR059809(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR059809A1 publication Critical patent/AR059809A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los anticuerpos anti-5T4, anti-5T4 conjugados como anticuerpo/fármaco, y métodos para su preparacion y uso. Reivindicacion 1: Un anticuerpo que se fija específicamente a antígeno 5T4 humano, en donde el anticuerpo; (a) comprende un dominio fijador de antígeno de los anticuerpos A1, A2 o A3 murinos; (b) compite por la fijacion de 5T4 con anticuerpos A1, A2 o A3 murinos; (c) se fija al epitopo 5T4 fijado por los anticuerpos A1, A2 o A3; o (d) comprende un fragmento fijador de 5T4 de un anticuerpo de (a)-(c).
ARP070100988A 2006-03-10 2007-03-09 Anticuerpos anti-5t4 y sus usos AR059809A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78134606P 2006-03-10 2006-03-10
US89124807P 2007-02-23 2007-02-23

Publications (1)

Publication Number Publication Date
AR059809A1 true AR059809A1 (es) 2008-04-30

Family

ID=38445207

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100988A AR059809A1 (es) 2006-03-10 2007-03-09 Anticuerpos anti-5t4 y sus usos

Country Status (30)

Country Link
US (5) US8044178B2 (es)
EP (3) EP2368914B1 (es)
JP (1) JP5523824B2 (es)
KR (2) KR101443752B1 (es)
CN (1) CN101437850B (es)
AR (1) AR059809A1 (es)
AU (1) AU2007226696C1 (es)
BR (1) BRPI0708771B8 (es)
CA (1) CA2645097C (es)
CR (1) CR10273A (es)
DK (2) DK1994055T3 (es)
EC (1) ECSP088733A (es)
ES (2) ES2498517T3 (es)
GT (1) GT200800181A (es)
HK (1) HK1121473A1 (es)
IL (2) IL193986A (es)
MX (1) MX2008011492A (es)
MY (1) MY148763A (es)
NO (1) NO20083891L (es)
NZ (2) NZ596295A (es)
PA (1) PA8718601A1 (es)
PE (1) PE20080119A1 (es)
PL (1) PL1994055T3 (es)
PT (1) PT1994055E (es)
SA (1) SA07280101B1 (es)
SG (1) SG170091A1 (es)
SI (1) SI1994055T1 (es)
TW (2) TWI421257B (es)
WO (1) WO2007106744A2 (es)
ZA (1) ZA200808075B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070243191A1 (en) * 2005-12-23 2007-10-18 The Board Of Regents Of The University Of Texas System Anti-hyperproliferative therapies targeting hdgf
AU2007226696C1 (en) 2006-03-10 2016-02-04 Wyeth Llc Anti-5T4 antibodies and uses thereof
PE20081216A1 (es) 2006-09-01 2008-09-04 Therapeutic Human Polyclonals Inc Expresion mejorada de la inmunoglobulina humana o humanizada en animales transgenicos no humanos
US9340774B2 (en) 2009-03-27 2016-05-17 Wyeth Llc Tumor-initiating cells and methods for using same
GB0918383D0 (en) 2009-10-20 2009-12-02 Cancer Rec Tech Ltd Prognostic,screening and treatment methods and agents for treatment of metastasis and inflammation
RU2012147249A (ru) 2010-04-07 2014-05-20 Эббви Инк. TNF-α- СВЯЗЫВАЮЩИЕ БЕЛКИ
WO2012109282A2 (en) * 2011-02-07 2012-08-16 Agamin Pharmaceuticals, Llc Methods and systems for treating or preventing pregnancy-related hypertensive disorders
MX342860B (es) * 2011-04-01 2016-10-14 Wyeth Llc Conjugados de anticuerpo-fármaco.
BR112014004162A2 (pt) 2011-08-22 2018-04-24 Cangene Corp anticorpos contra clostridium difficile
CA2846432A1 (en) 2011-09-23 2013-03-28 Amgen Research (Munich) Gmbh Bispecific binding molecules for 5t4 and cd3
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
BR112014018192A8 (pt) 2012-01-24 2021-03-02 Epic Sciences Inc método e kit para detecção de células tumorais circulantes 5t4-positivas, bem como métodos de diagnóstico de câncer 5t4-positivo e de seleção para atividade e eficácia de conjugado fármaco-anticorpo para tratamento de câncer
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
JP6572131B2 (ja) 2012-12-12 2019-09-04 バスキュロックス インコーポレイテッド 治療用ｃｄ４７抗体
WO2014137931A1 (en) * 2013-03-06 2014-09-12 Imaginab, Inc. Antigen binding constructs to 5t4
WO2014160183A1 (en) 2013-03-13 2014-10-02 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
JP2016531088A (ja) * 2013-06-17 2016-10-06 アサナ・バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー ５ｔ４標的化免疫融合分子および方法
MX367851B (es) 2013-10-11 2019-09-09 Mersana Therapeutics Inc Conjugados de proteína-polímero-fármaco.
ES2754397T3 (es) 2013-10-11 2020-04-17 Asana Biosciences Llc Conjugados de proteína-polímero-fármaco
AU2014342610A1 (en) 2013-11-04 2016-06-02 Abbvie Stemcentrx Llc Anti-EFNA4 antibody-drug conjugates
WO2015155345A1 (en) * 2014-04-11 2015-10-15 Medimmune Limited Antibodies and antibody-drug conjugates
DK3151865T3 (da) 2014-05-22 2021-10-25 Byondis Bv Stedsspecifik konjugation af linker medicin til antistof og resulterende adcs
TWI707872B (zh) 2014-05-29 2020-10-21 美商宏觀基因股份有限公司 特異性結合多種癌症抗原的三特異性結合分子和其使用方法
AU2015295349B2 (en) 2014-07-29 2020-09-24 Cellectis ROR1(NTRKR1)specific chimeric antigen receptors for cancer immunotherapy
CA2956482A1 (en) 2014-07-31 2016-02-04 Cellectis Ror1 specific multi-chain chimeric antigen receptor
EP3699188A1 (en) 2014-09-04 2020-08-26 Cellectis 5t4 (tpbg) specific chimeric antigen receptors for cancer immunotherapy
US20160251417A1 (en) * 2015-01-22 2016-09-01 Prothena Biosciences Limited Antibodies recognizing medin
EP3298046A1 (en) 2015-05-20 2018-03-28 Cellectis Anti-gd3 specific chimeric antigen receptors for cancer immunotherapy
JP6885606B2 (ja) 2015-09-18 2021-06-16 アーチ オンコロジー, インコーポレイテッドArch Oncology, Inc. 治療用ｃｄ４７抗体
EP3184547A1 (en) * 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
MY187325A (en) * 2015-11-24 2021-09-22 Byondis Bv Anti-5t4 antibodies and antibody-drug conjugates
EP3395834A4 (en) * 2015-12-24 2019-10-23 XDCExplorer (Shanghai) Co., Ltd. ANTI-TPBG ANTIBODIES AND ITS PREPARATION METHOD, CONJUGATED AND USE THEREOF
MX2019000727A (es) * 2016-07-20 2019-05-02 Aerpio Therapeutics Inc Anticuerpos monoclonales humanizados que tienen como blanco ve-ptp (hptp-b).
WO2018075960A1 (en) 2016-10-21 2018-04-26 Tioma Therapeutics, Inc. Therapeutic cd47 antibodies
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
CN108084265B (zh) * 2016-11-23 2021-07-02 复旦大学 特异性结合人的5t4抗原的全人源单域抗体及其应用
CN108285487B (zh) * 2017-01-08 2021-02-19 浙江昭华生物医药有限公司 抗5t4抗体-药物偶联物及其应用
US11459394B2 (en) 2017-02-24 2022-10-04 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
KR20230166145A (ko) 2017-03-15 2023-12-06 옥스포드 바이오메디카(유케이) 리미티드 방법
WO2018184558A1 (zh) * 2017-04-05 2018-10-11 凯惠科技发展(上海)有限公司 一种人源化抗tpbg抗体及其制备方法、其偶联物和应用
CA3058477A1 (en) 2017-04-11 2018-10-18 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
US20200165351A1 (en) * 2017-06-06 2020-05-28 The Regents Of The University Of California Humanized anti-n-cadherin antibodies and uses thereof
NZ761636A (en) 2017-07-20 2023-07-28 Aptevo Res & Development Llc Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
US11638760B2 (en) 2017-11-27 2023-05-02 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
CN111757757A (zh) 2017-12-21 2020-10-09 梅尔莎纳医疗公司 吡咯并苯并二氮呯抗体共轭物
CN108187065B (zh) * 2017-12-29 2023-04-28 广东众生药业股份有限公司 抗5t4抗体与美登素衍生物dm4偶联复合物及制备方法和用途
AU2019205912A1 (en) 2018-01-03 2020-07-16 Palleon Pharmaceuticals Inc. Recombinant human sialidases, sialidase fusion proteins, and methods of using the same
BR112020018490A2 (pt) 2018-03-12 2020-12-29 Genmab A/S Anticorpo, imunoconjugado ou conjugado de anticorpo-fármaco, construção de ácido nucléico, vetor de expressão, célula, composição, composição farmacêutica, anticorpo, método, método para produzir um anticorpo, kit de partes, e, anticorpo anti-idiotípico
BR112020020604A2 (pt) 2018-04-11 2021-01-12 Inhibrx, Inc. Construções de polipeptídeo multiespecífico tendo ligação restrita de cd3 e métodos e usos relacionados
TW202035451A (zh) 2018-07-24 2020-10-01 美商英伊布里克斯公司 含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法
JP7453219B2 (ja) 2018-10-11 2024-03-19 インヒブリックス， インコーポレイテッド Ｐｄ－１単一ドメイン抗体およびその治療用組成物
CA3117050A1 (en) 2018-10-29 2020-05-07 Mersana Therapeutics, Inc. Cysteine engineered antibody-drug conjugates with peptide-containing linkers
WO2021048423A1 (en) 2019-09-12 2021-03-18 Genmab A/S Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer
JP2023513003A (ja) 2020-01-29 2023-03-30 インヒブルクス インコーポレイテッド Ｃｄ２８シングルドメイン抗体ならびにその多価および多重特異性の構築物
JP2023546679A (ja) * 2020-10-22 2023-11-07 アクティニウム ファーマシューティカルズ インコーポレイテッド がん治療における放射免疫療法とｃｄ４７遮断の併用
EP4274614A1 (en) * 2021-01-06 2023-11-15 Palleon Pharmaceuticals Inc. Anti-pd-l1 antibodies and fusion proteins thereof
WO2023155925A1 (en) * 2022-02-21 2023-08-24 Concept To Medicine Biotech Co., Ltd. Anti-5t4 antibodies and uses thereof
EP4353220A1 (en) * 2022-10-12 2024-04-17 Pierre Fabre Medicament Use of a liquid aqueous composition for solubilization and stabilization of an antibody-drug conjugate

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5037651A (en) 1987-01-30 1991-08-06 American Cyanamid Company Dihydro derivatives of LL-E33288 antibiotics
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US5108912A (en) 1987-01-30 1992-04-28 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5869053A (en) 1988-03-04 1999-02-09 Cancer Research Campaign Technology, Ltd. 5T4 antigen from human trophoblasts
WO1989007947A1 (en) * 1988-03-04 1989-09-08 Cancer Research Campaign Technology Limited Improvements relating to antigens
KR0162259B1 (ko) 1989-12-05 1998-12-01 아미 펙터 감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
GB9116610D0 (en) 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
US6310185B1 (en) 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
ZA955642B (en) 1994-07-07 1997-05-06 Ortho Pharma Corp Lyophilized imaging agent formulation
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
WO1997026885A1 (en) 1996-01-23 1997-07-31 The General Hospital Corporation Doing Business As Massachusetts General Hospital Benzophenothiazine and benzoporphyrin dye combination photodynamic therapy of tumors
CN1224712C (zh) 1997-06-04 2005-10-26 牛津生物医学（英国）有限公司 载体
GB2370573A (en) 1998-11-18 2002-07-03 Oxford Biomedica Ltd Poxviral vectors
GB2378704B (en) 1998-11-18 2003-05-07 Oxford Biomedica Ltd Uses of 5t4 antigen
EP2042598A1 (en) 1998-11-18 2009-04-01 Oxford Biomedica (UK) Limited 5T4 tumour-associated antigen for use in tumour immunotherapy
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
EP1396543A3 (en) * 1999-07-08 2004-03-31 Research Association for Biotechnology Primers for synthesizing full length cDNA clones and their use
AU2001257577A1 (en) 2000-02-28 2001-09-03 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
NZ524523A (en) 2000-08-03 2006-02-24 Therapeutic Human Polyclonals Production of humanized antibodies in transgenic animals
WO2002038612A2 (en) * 2000-11-13 2002-05-16 Oxford Biomedica (Uk) Limited Canine and feline tumour-associated antigen 5t4
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
WO2002100326A2 (en) 2001-05-01 2002-12-19 The General Hospital Corporation Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
GB0126378D0 (en) * 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
GB0203419D0 (en) * 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
WO2003080672A1 (en) 2002-03-22 2003-10-02 Aprogen, Inc. Humanized antibody and process for preparing same
BR122019027966B8 (pt) 2002-05-02 2021-07-27 Wyeth Corp conjugado monomérico de derivado de caliqueamicina/anti-corpo anti-cd22 e uso dos mesmos
AR048098A1 (es) 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
WO2006004950A2 (en) 2004-06-30 2006-01-12 International Bioimmune Systems, Inc. Humanized monoclonal antibody 31.1 as an anticancer agent
WO2006031653A2 (en) 2004-09-10 2006-03-23 Wyeth Humanized anti-5t4 antibodies and anti-5t4 antibody / calicheamicin conjugates
BRPI0516572A (pt) * 2004-10-05 2008-09-16 Wyeth Corp métodos e composições para melhorar a produção de proteìnas recombinantes
AU2007226696C1 (en) * 2006-03-10 2016-02-04 Wyeth Llc Anti-5T4 antibodies and uses thereof
KR101901555B1 (ko) 2010-04-21 2018-09-21 신타가 비.브이. Ｃｃ―１０６５ 유사체와 2작용성 링커의 신규한 콘쥬게이트
MX342860B (es) * 2011-04-01 2016-10-14 Wyeth Llc Conjugados de anticuerpo-fármaco.

Also Published As

Publication number Publication date
EP2368914B1 (en) 2019-01-02
US20140308302A1 (en) 2014-10-16
BRPI0708771B1 (pt) 2019-10-22
US20120064600A1 (en) 2012-03-15
KR20080106345A (ko) 2008-12-04
AU2007226696B2 (en) 2013-08-29
US20160185859A1 (en) 2016-06-30
NZ571208A (en) 2011-12-22
ES2498517T3 (es) 2014-09-24
HK1121473A1 (en) 2009-04-24
US20070231333A1 (en) 2007-10-04
ECSP088733A (es) 2008-10-31
AU2007226696A1 (en) 2007-09-20
WO2007106744A8 (en) 2008-10-02
KR101443752B1 (ko) 2014-09-26
CN101437850B (zh) 2013-10-09
JP5523824B2 (ja) 2014-06-18
TW200804424A (en) 2008-01-16
KR20130018980A (ko) 2013-02-25
BRPI0708771A2 (pt) 2011-06-14
KR101264216B1 (ko) 2013-05-31
BRPI0708771B8 (pt) 2021-05-25
AU2007226696C1 (en) 2016-02-04
PT1994055E (pt) 2014-09-15
CR10273A (es) 2008-11-26
EP1994055A2 (en) 2008-11-26
GT200800181A (es) 2010-05-25
JP2009529578A (ja) 2009-08-20
CA2645097C (en) 2019-09-17
PE20080119A1 (es) 2008-03-04
CA2645097A1 (en) 2007-09-20
WO2007106744A2 (en) 2007-09-20
EP1994055B1 (en) 2014-07-02
TW201335189A (zh) 2013-09-01
SG170091A1 (en) 2011-04-29
CN101437850A (zh) 2009-05-20
ES2712942T3 (es) 2019-05-16
NO20083891L (no) 2008-12-03
NZ596295A (en) 2013-01-25
WO2007106744A3 (en) 2007-11-29
TWI421257B (zh) 2014-01-01
SI1994055T1 (sl) 2014-08-29
RU2008137074A (ru) 2010-04-20
US8044178B2 (en) 2011-10-25
US9902771B2 (en) 2018-02-27
PA8718601A1 (es) 2009-05-15
DK2368914T3 (en) 2019-03-04
IL240245A (en) 2017-05-29
US8759495B2 (en) 2014-06-24
MY148763A (en) 2013-05-31
EP2368914A1 (en) 2011-09-28
PL1994055T3 (pl) 2015-02-27
MX2008011492A (es) 2008-09-22
TWI409277B (zh) 2013-09-21
IL240245A0 (en) 2015-09-24
DK1994055T3 (da) 2014-08-25
EP3539989A1 (en) 2019-09-18
IL193986A (en) 2015-08-31
SA07280101B1 (ar) 2011-10-03
ZA200808075B (en) 2012-03-28
US20180162937A1 (en) 2018-06-14
IL193986A0 (en) 2011-08-01

Similar Documents

Publication Publication Date Title
AR059809A1 (es) Anticuerpos anti-5t4 y sus usos
BRPI0611414B8 (pt) anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga ao tweak humano, composição farmacêutica e seus usos
CY1121536T1 (el) Ανθρωπινα αντισωματα εναντι-αλφα-συνουκλεϊνης
BRPI0515113A (pt) anticorpos anti-5t4 humanizados e conjugados de anticorpo anti-5t4/caliqueamicina
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
AR059922A1 (es) Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
UA109633C2 (uk) Антитіло людини проти тканинного фактора
CR20130016A (es) ANTICUERPOS PEPTIDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
EA201391159A1 (ru) Hla-рестриктированные пептидоспецифические антигенсвязывающие белки
PE20141659A1 (es) Dominios variables singulares anti-vgf fusionados con dominios de fc
NI201000281A (es) Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso.
ECSP10010653A (es) Anticuerpos anti-il-17a/il-17f de reactividad cruzada y métodos de uso de los mismos
RS54113B1 (en) COMPOSITIONS AND PROCEDURES FOR ANTIBODIES ON THE C5 COMPLEMENTARY PROTEIN
BRPI0607486A2 (pt) anticorpo l243 humanizado, anticorpo biespecìfico ou fragmentos de ligação a antìgeno dos mesmos, composição farmacêutica, kit e uso dos referidos anticorpos
NI200700315A (es) Anticuerpos monoclonales anti-trkb y usos de los mismos.
PE20110668A1 (es) Anticuerpos anti-linfopoyetina estromal timica (anti-tslp)
BR112012023010A2 (pt) "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37"
CL2007002800A1 (es) Anticuerpo monoclonal anti-receptor a de interleucina 17 (il-17ra) o fragmento de union a antigeno del mismo; polinucleotido que lo codifica; metodo de preparacion; y metodo para tratar un trastorno influido por la activacion de il-17ra.
AR061246A1 (es) Anticuerpos anti- dill4 y metodos que los usan
CO6231040A2 (es) Moleculas y metodos para modular la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
CO6280500A2 (es) Anticuerpos humanizados especificos pare l factor von willebrand
ECSP088241A (es) Un conjugado citotóxico ca6 antígeno-específico y métodos para utilizar el mismo
AR069290A1 (es) Anticuerpos monoclonales que se unen al hgm -csf (factor estimulante de la colonia de granulocitos-macrofagos) y las composiciones medicas que los comprenden
AR062268A1 (es) Agentes ligantes direccionados dirigidos a pdgfr-alfa y sus usos

Legal Events

Date Code Title Description
FG Grant, registration